Recombinant Mouse IL-7Ra/CD127 protein (rFc Tag)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg1826

---

Validation Data Gallery

• 

  Purity of Recombinant Mouse IL-7Ra was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Mouse IL-7Ra protein Glu21-Asp239 (Accession# P16872) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 16197
• Accession: P16872
• PredictedSize: 51.3 kDa
• SDS-PAGE: 58-68 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CD127, also known as IL-7R subunit alpha (IL-7Rα), is a type I membrane glycoprotein expressed in thymocytes, B cell precursors, most T cells, and some lymphoid and myeloid cells. IL-7R is a heterodimer composed of CD127 and IL-2Rγ (CD132), which is a common gamma chain shared by the receptors of various cytokines, including interleukins 2, 4, 7, 9, and 15. IL-7R plays critical roles in lymphocyte development and homeostasis. CD127 can also act as a receptor for thymic stromal lymphopoietin (TSLP).

References:

1.Sudo T, et al.(1993) Proc Natl Acad Sci U S A. 90(19):9125-9.
2.Noguchi M, et al. (1993) Science. 262(5141):1877-80.
3.He YW, et al. (1998) Crit Rev Immunol. 18(6):503-24.
4.Abe A, et al. (2015) J Immunol. 195(7):3129-38.
5.Park LS, et al.(2000) J Exp Med. 192(5):659-70.